We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+19.88%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.1B
AUM Growth
+$208M
Cap. Flow
+$144M
Cap. Flow %
13.12%
Top 10 Hldgs %
54.38%
Holding
136
New
36
Increased
27
Reduced
26
Closed
32

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$35.5M
2
NVO
Novo Nordisk
NVO
+$19.7M
3
URGN icon
UroGen Pharma
URGN
+$12.9M
4
BMY icon
Bristol-Myers Squibb
BMY
+$12.4M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$10.9M

Top Sells

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$19.7M
2
CELG
Celgene Corp
CELG
+$18.8M
3
ITRN icon
Ituran Location and Control
ITRN
+$14.6M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$11.6M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 55.27%
2 Technology 6.57%
3 Consumer Discretionary 1.18%
4 Industrials 1.08%
5 Communication Services 0.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
26
Ascendis Pharma A/S
ASND
$16B
$8.04M 0.73%
68,273
+10,000
+17% +$876K
SYRE icon
27
Spyre Therapeutics
SYRE
$8.54B
$7.85M 0.72%
39,000
+15,000
+63% +$3.13M
ALLT icon
28
Allot
ALLT
$372M
$7.67M 0.7%
965,931
+370,167
+62% +$2.66M
PANW icon
29
Palo Alto Networks
PANW
$270B
$7.47M 0.68%
184,524
+35,214
+24% +$1.31M
CSTE icon
30
Caesarstone
CSTE
$72.3M
$7.46M 0.68%
478,114
+8,954
+2% +$140K
MSFT icon
31
Microsoft
MSFT
$3.45T
$7.24M 0.66%
61,397
+14,399
+31% +$1.57M
AERI
32
DELISTED
Aerie Pharmaceuticals
AERI
$7.13M 0.65%
+150,000
New +$6.6M
BIIB icon
33
Biogen
BIIB
$30B
$7.09M 0.65%
+30,000
New +$9.45M
RETA
34
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$6.99M 0.64%
81,769
-139,500
-63% -$11.6M
ARQL
35
DELISTED
Arqule Inc
ARQL
$6.86M 0.63%
1,432,643
-600,000
-30% -$2.32M
SIOX
36
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$6.79M 0.62%
638,542
-386,458
-38% -$3.85M
IMMU
37
DELISTED
Immunomedics Inc
IMMU
$6.28M 0.57%
326,660
-379,879
-54% -$6.12M
CAMT icon
38
Camtek
CAMT
$6.18B
$6.25M 0.57%
+700,574
New +$5.67M
AUTL
39
Autolus Therapeutics
AUTL
$407M
$6.07M 0.55%
192,994
-10,000
-5% -$284K
KRYS icon
40
Krystal Biotech
KRYS
$10.1B
$5.97M 0.55%
181,625
+7,000
+4% +$165K
TVRD
41
Tvardi Therapeutics
TVRD
$19.7M
$5.96M 0.54%
8,443
– –
GOOGL icon
42
Alphabet (Google) Class A
GOOGL
$4.36T
$5.88M 0.54%
+100,000
New +$5.65M
MYOK
43
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$5.88M 0.54%
+113,000
New +$5.21M
MLNX
44
DELISTED
Mellanox Technologies, Ltd.
MLNX
$5.85M 0.53%
49,394
+21,043
+74% +$2.12M
NEOS
45
DELISTED
Neos Therapeutics, Inc
NEOS
$5.75M 0.52%
2,201,697
– –
XENE icon
46
Xenon Pharmaceuticals
XENE
$6.06B
$5.42M 0.49%
533,655
+84,171
+19% +$714K
AMZN icon
47
Amazon
AMZN
$2.92T
$5.34M 0.49%
+60,000
New +$4.99M
ANAB icon
48
AnaptysBio
ANAB
$1.58B
$5.11M 0.47%
+70,000
New +$4.83M
RCKT icon
49
Rocket Pharmaceuticals
RCKT
$340M
$5.09M 0.46%
290,001
– –
NERV icon
50
Minerva Neurosciences
NERV
$185M
$5.05M 0.46%
80,252
-17,500
-18% -$1.05M
1
2
3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2019 Portfolio in Review

As of Q1 2019, Sphera Funds Management held 136 positions worth $1.1B, up 23% from $887M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sphera Funds Management deployed $144M of net new capital in Q1 2019, opening 36 new positions and adding to 27 existing holdings. Its largest new stake was Johnson & Johnson: 265,000 shares worth $37M.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 60% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Viatris, an estimated $19.7M trimmed.

  • Sphera Funds Management's largest Q1 2019 buy was Johnson & Johnson: 265,000 shares worth $37M.
  • Sphera Funds Management added most to Bristol-Myers Squibb in Q1 2019, an estimated $12.4M increase.
  • Sphera Funds Management's biggest Q1 2019 reduction was Viatris, cutting an estimated $19.7M.
  • Sphera Funds Management fully exited Ituran Location and Control in Q1 2019, selling an estimated $14.6M.
  • Sphera Funds Management's ten largest holdings make up 54% of its $1.1B portfolio in Q1 2019.
  • Sphera Funds Management opened 36 new positions and closed 32 in Q1 2019.
  • Sphera Funds Management's portfolio value rose 23% quarter-over-quarter to $1.1B.

Based on Sphera Funds Management's 13F filing for Q1 2019, filed 15 May 2019.